🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Nicely done review covering recent advances using #CART cells for #glioblastoma Penn Neurosurgery Penn Medicine

I will present our 10-year #CART cell clinical experience with #glioblastoma at Penn Medicine - Abramson Cancer Center Penn Medicine this Wednesday am at #PEGS2024 meeting in Boston. Looking forward to generating additional interest in our program as we develop new therapies for #GBM

Let’s talk Wednesday if you’re free #GBM

You forgot the option -> NONE

Agree- Jim has advanced the Orphan disease center at Penn and made significant advances! #AAV

This is one of the worst takes on how we approach patients I have ever heard- get yourself informed

We have received remarkable support from Penn Medicine - Abramson Cancer Center and the Center for Cellular Immunotherapy at Penn Medicine led by Carl June for our #glioblastoma #CART trials and believe strongly in progress leading to FDA-approved products in this time frame

This is a massive overreach - AI driven discovery does not account for biological complexity which is the major challenge in drug evaluation and approval

You should do a Substack - this is a great resource !

Important talk! Great to see this !@PennNSG

Our group recently also showed that TGFb disruption enhanced our bivalent CART cell approach currently in P1 for recurrent #glioblastoma cell.com/action/showPdf…

Great news for Penn Medicine and Penn Medicine - Abramson Cancer Center - Daniel if you have interest in #glioblastoma let’s talk soon or at Parker Institute for Cancer Immunotherapy to discuss new #CART cell design for #GBM

Very pleased to report that our trial results discussed here by Carl June have been extended to 14 patients to date and we are seeing longer survival in recurrent #glioblastoma with bivalent #CART cells - this approach was developed by my team at Penn Medicine - Abramson Cancer Center in the #GBM Center

Patient-derived glioblastoma organoids as real-time avatars for assess... sciencedirect.com/science/articl… Happy to report our work using #GBM organoids to predict #CART response in #glioblastoma Penn Medicine - Abramson Cancer Center

He wasn’t part of the ticket and is a threat to the health of all Americans including children. I urge you to reconsider your position #RFKJr should not be confirmed

I find this sentiment from a reporter on the biotech sector to be both alarming and grotesquely simplified. Perhaps you don’t warrant the platform you have for new innovation? #RFK is a disaster for health at home and abroad

#ASCO25 Tune into the “Turning ‘Cold’ Tumors ‘Hot’” Clinical Science Symposium tomorrow morning to hear more from Stephen Bagley on CAR T cell therapy for recurrent #glioblastoma. Abstract 102. Penn Neurosurgery DrORourke

Katy congratulations to your group - this is a big advance towards the goal of making CAR-NKs a therapeutic reality